Biosecurity Modernization and Innovation Act

On August 31, 2026, Representative Pfluger (R-TX) introduced H.R. 10197, the Biosecurity Modernization and Innovation Act, with bipartisan cosponsor Houlahan (D-PA). The bill was referred to the House Committee on Energy and Commerce — an early legislative stage. The bill requires any entity that makes nucleic acid sequences available in commerce to establish a program for identity verification, purpose determination, identifying high-risk sequences, refusing sales to risky buyers, notifying the Secretary of suspicious buyers, undergoing independent compliance assessments (including adversarial testing and third-party audits), and maintaining records for at least five years.

There is no authorized funding or new spending in this bill. The mechanism is a compliance mandate on private companies, not a procurement contract or grant program. The money trail is indirect: covered entities must spend on internal protocols, audits, and potential technology upgrades to meet the screening and recordkeeping requirements. This is a cost imposition, but for incumbents that already operate robust screening, the incremental cost is modest relative to the competitive moat created — smaller or less-scrupulous providers will face higher hurdles to market entry.

No convergence data was provided, so this bill stands alone as a single regulatory signal. However, it fits within a broader policy trend toward biosecurity regulation, driven by concerns over DNA synthesis misuse. The bill's bipartisan sponsorship suggests it could advance, but as an early-stage referral to committee, the legislative path remains uncertain. Next steps: committee markup, then floor vote in the House, companion bill in the Senate, and potential amendment.

Structural winners are established providers with existing biosecurity programs: Twist Bioscience ($TWST), the leading pure-play gene synthesis company, and Ginkgo Bioworks ($DNA), which operates a cell programming foundry that uses and potentially supplies synthetic DNA. Both have already invested in screening infrastructure. Diversified life science tools companies (Thermo Fisher $TMO, Danaher $DHR) are less exposed because synthesis revenue is a small fraction of their total. The bill does not create losers beyond smaller non-public synthesis shops that may struggle with compliance costs.

Timeline: The 180-day guidance period after enactment starts the clock, but the bill is only at referral stage. A realistic timeline for passage (if it moves) would be late 2026 or 2027, likely requiring subsequent Congress action.